Non-Interventional Study To Investigate Whether Information Provided To Patients Influences Their Satisfaction With Toviaz Therapy
NCT01091519
Last updated date
ABOUT THIS STUDY
Collect information on treatment with Toviaz (fesoterodine) under ordinary prescribing
conditions, and to investigate whether additional educational information affects
satisfaction with treatment as perceived by the patient.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Overactive Urinary Bladder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
Patients with increased urinary frequency and/or imperative urgency and/or urge incontinence, as can occur in patients with overactive bladder syndrome, for whom Toviaz was prescribed for treatment of the symptoms.
Patients will complete the OABv8 questionnaire and will need to meet a minimum score in order to be eligible for the study.
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
Patients who meet the contraindications in the Toviaz prescribing information (active
ingredient fesoterodine) will be excluded.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Clinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Overactive Urinary BladderA Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring
NCT00646880
- Seoul,
ALL GENDERS
20 Years+
years
MULTIPLE SITES
Overactive Urinary BladderA Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.
NCT00798434
- Wien,
- Antwerpen,
- Edegem,
- Gent,
- Kortrijk,
- Aarhus N,
- Glostrup,
- Helsinki,
- Kouvola,
- OYS,
- Tampere,
- Turku,
- Berlin,
- Berlin,
- Frankfurt,
- Hannover,
- Leipzig,
- Muenchen,
- Haifa,
- Haifa,
- Jerusalem,
- Foggia,
- Terracina, LT,
- Hamar,
- Oslo,
- Tonsberg,
- Trondheim,
- Coimbra,
- Lisboa,
- Porto,
- Porto,
- Porto,
- Bratislava,
- Bratislava,
- Galanta,
- Kosice - Saca,
- Kosice,
- Martorell, Barcelona
- Sabadell, Barcelona
- Getafe, Madrid
- Manacor, Palma de Mallorca
- Valencia,
- Eslov,
- Goteborg,
- Malmo,
- Malmo,
- Norrkoping,
- Stockholm,
- Frauenfeld,
- Ankara,
- Istanbul,
- Izmir,
- Samsun,
- Bexhill on Sea, East Sussex
- Leytonstone, London
- Harrow, Middlesex
- High Heaton, Newcastle upon Tyne
- Birmingham,
- London,
- London,
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Overactive Urinary BladderA Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.
NCT00645281
- Birmingham, Alabama
- Birmingham, Alabama
- Birmingham, Alabama
- Huntsville, Alabama
- Montgomery, Alabama
- Phoenix, Arizona
- Sun Lakes, Arizona
- Bentonville, Arkansas
- Jonesboro, Arkansas
- Little Rock, Arkansas
- Buena Park, California
- Foothill Ranch, California
- Fresno, California
- West Covina, California
- Colorado Springs, Colorado
- Lakewood, Colorado
- Chipley, Florida
- Davie, Florida
- Hallandale, Florida
- Miami Beach, Florida
- Miami, Florida
- Murdock, Florida
- Ocala, Florida
- Pembroke Pines, Florida
- St. Cloud, Florida
- Tampa, Florida
- Atlanta, Georgia
- Barnesville, Georgia
- Blue Ridge, Georgia
- Decatur, Georgia
- Chicago, Illinois
- Naperville, Illinois
- Orland Park, Illinois
- Newton, Kansas
- Shawnee, Kansas
- Wichita, Kansas
- Wichita, Kansas
- Marrero, Louisiana
- Laurel, Maryland
- Oxon Hill, Maryland
- Jackson, Michigan
- Portage, Michigan
- St. Louis, Missouri
- Las Vegas, Nevada
- Las Vegas, Nevada
- Blackwood, New Jersey
- Mt. Laurel, New Jersey
- Binghamton, New York
- Endicott, New York
- Endwell, New York
- Kingston, New York
- Beaufort, North Carolina
- Charlotte, North Carolina
- Charlotte, North Carolina
- Durham, North Carolina
- Morehead City, North Carolina
- Winston-Salem, North Carolina
- Columbus, Ohio
- Kettering, Ohio
- Central Point, Oregon
- Medford, Oregon
- Bala Cynwyd, Pennsylvania
- Bensalem, Pennsylvania
- Connellsville, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Sellersville, Pennsylvania
- Stoneboro, Pennsylvania
- Warwick, Rhode Island
- Greer, South Carolina
- Simpsonville, South Carolina
- Cordova, Tennessee
- Huntingdon, Tennessee
- Lexington, Tennessee
- Savannah, Tennessee
- Selmer, Tennessee
- Waynesboro, Tennessee
- Austin, Texas
- Bryan, Texas
- Colleyville, Texas
- Friendswood, Texas
- Houston, Texas
- Plano, Texas
- Plano, Texas
- San Antonio, Texas
- Salt Lake City, Utah
- Salt Lake City, Utah
- West Jordan, Utah
- West Valley City, Utah
- Spokane, Washington
- Spokane, Washington
- Milwaukee, Wisconsin
- New Berlin, Wisconsin
- Oregon, Wisconsin
- Wauwatosa, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Overactive Urinary BladderPharmacokinetics and Relative Bioavailability Study
NCT01521767
- Singapore,
ALL GENDERS
21 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | Non-Interventional Study To Investigate Whether Information Provided To Patients Influences Their Satisfaction With Toviaz Therapy | |||
| Official Title | Facts Study (Fakten-studie): Non-interventional Study to Investigate Whether Information Provided to Patients Influences Satisfaction With Toviaz Therapy As Perceived by the Patient | |||
| Brief Summary | Collect information on treatment with Toviaz (fesoterodine) under ordinary prescribing conditions, and to investigate whether additional educational information affects satisfaction with treatment as perceived by the patient. | |||
| Detailed Description | Patients will be identified and monitored during routine clinical practice visits, and will not be specifically selected as this would interfere with the representativeness of the results. The study will be conducted with office-based urologists and office-based general physicians, practitioners and internists (GPs) in Germany, thus representing a wide range of practices and populations. Each urologist or GP may invite patients to participate who have already been diagnosed with overactive bladder and prescribed Toviaz according to their usual standard of care. Study enrollment stopped on December 31, 2011 due to difficulty in recruiting patients. No safety issues were related to the decision to stop patient enrollment. | |||
| Study Type | Observational | |||
| Study Design | Time Perspective: Prospective | |||
| Target Follow-Up Duration | Not Provided | |||
| Biospecimen | Not Provided | |||
| Sampling Method | Non-Probability Sample | |||
| Study Population | Patients with overactive bladder symptoms presenting during routine clinical practice visits | |||
| Condition | Urinary Bladder, Overactive | |||
| Intervention |
| |||
| Study Groups/Cohorts |
| |||
| Publications * | Schneider T, Arumi D, Crook TJ, Sun F, Michel MC. An observational study of patient satisfaction with fesoterodine in the treatment of overactive bladder: effects of additional educational material. Int J Clin Pract. 2014 Sep;68(9):1074-80. doi: 10.1111/ijcp.12450. Epub 2014 May 5. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status | Terminated | |||
| Actual Enrollment | 781 | |||
| Original Estimated Enrollment | 3771 | |||
| Actual Study Completion Date | May 2012 | |||
| Actual Primary Completion Date | May 2012 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria | Inclusion Criteria: Patients with increased urinary frequency and/or imperative urgency and/or urge incontinence, as can occur in patients with overactive bladder syndrome, for whom Toviaz was prescribed for treatment of the symptoms. Patients will complete the OABv8 questionnaire and will need to meet a minimum score in order to be eligible for the study. Exclusion Criteria: Patients who meet the contraindications in the Toviaz prescribing information (active ingredient fesoterodine) will be excluded. | |||
| Sex/Gender |
| |||
| Ages | 18 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers | No | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Not Provided | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT01091519 | |||
| Other Study ID Numbers | A0221073 FACTS (FAKTEN) study | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement | Not Provided | |||
| Responsible Party | Pfizer | |||
| Study Sponsor | Pfizer | |||
| Collaborators | Not Provided | |||
| Investigators |
| |||
| PRS Account | Pfizer | |||
| Verification Date | January 2013 | |||